In addition, the effects of JAK inhibitors including filgotinib are non-inferior or superior to those of tumor necrosis factor (TNF) inhibitors in patients with active RA and an inadequate response to MTX [6–9]; however, to date, no head-to-head comparison between JAK inhibitors and IL-6 inhibitors has been performed. This evidence concerns the gene TNF and rheumatoid arthritis.